RT Journal Article
SR Electronic
T1 AI-VDT can Help in Detecting Primary Lung Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.26.22274299
DO 10.1101/2022.04.26.22274299
A1 Suzuki, Kazuhiro
A1 Otsuka, Yujiro
A1 Imashimizu, Kota
A1 Hata, Kazunori
A1 Suzuki, Kenji
YR 2022
UL http://medrxiv.org/content/early/2022/04/28/2022.04.26.22274299.abstract
AB The current study shows that measuring volume doubling time could accelerate the detection of primary lung cancer in chest CT imaging. Thirty tumors were selected from surgical cases of primary lung cancer at a university hospital in Japan, and the CT scan data and radiology reports were extracted retrospectively. The CT scan data were processed by a commercial pulmonary nodule AI and volume doubling time was calculated for each historical study time point. 43% of the 30 tumors had an VDT below 400 days in earlier study than the tumor was reported as a nodule on the radiology report. The average days of earlier detection was 299 days. Interpolation of the detailed mortality reduction data from the NELSON study predicted a 5.6% reduction in 10-year mortality from lung cancer.Competing Interest StatementYujiro Otsuka is am employee of Milliman, Inc. Yujiro Otsuka is a managing partner of Plusman LLC.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Hospital Ethics Committee of Juntendo Hospital gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors